Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Drops By 69.8%

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 30,400 shares, a drop of 69.8% from the November 15th total of 100,500 shares. Based on an average daily trading volume, of 494,200 shares, the short-interest ratio is currently 0.1 days.

Astellas Pharma Stock Performance

Astellas Pharma stock traded down $0.11 during mid-day trading on Wednesday, reaching $10.33. 393,266 shares of the company’s stock were exchanged, compared to its average volume of 233,922. The firm has a market capitalization of $18.69 billion, a PE ratio of 49.19 and a beta of 0.33. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. The business’s fifty day simple moving average is $11.09 and its 200 day simple moving average is $11.03. Astellas Pharma has a one year low of $9.15 and a one year high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $3.11 billion for the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. On average, sell-side analysts expect that Astellas Pharma will post 0.61 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.